Alkermes vs PTC Therapeutics
PTC Therapeutics reported revenue of $1.7 billion in fiscal 2025, 1.2 times Alkermes' $1.5 billion in fiscal 2025. Alkermes' revenue fell 5.2% in its latest year, and PTC Therapeutics' grew 114.5%. Alkermes had an operating margin of 17.2%, against 50.1% at PTC Therapeutics. Free cash flow was $480 million at Alkermes and $702 million at PTC Therapeutics.
Side by side
| Alkermes | PTC Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.5B | $1.7B |
| Revenue growth | −5.2% | 114.5% |
| Revenue growth a year, last 5 years | 7.3% | 35.4% |
| Gross margin | 86.7% | — |
| Operating margin | 17.2% | 50.1% |
| Net margin | 16.4% | 39.4% |
| Free cash flow | $480M | $702M |
| Free cash flow margin | 32.5% | 40.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.3% | 14.9% |
| Last close | $45.90 | $65.44 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $10.0 million | sold $55.5 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlkermesPTC Therapeutics
Operating margin
Percent of revenue
AlkermesPTC Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesPTC Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and PTC Therapeutics pages.